comparison of glp 1 drugs agonists Table 1 from Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Drug Class Review developed bundle cultivating targeted restoration across the Gut Medication vs. Bariatric Surgery for

Zannad, F

The drug should emerge as a first-line therapy for persons with type 2 diabetes and associated overweight/obesity as well as atherosclerotic cardiovascular disease

PMID: 38302593

Read on for a closer look at the science behind these drugs and the different opinions surrounding their increasingly popular role in weight loss

Compounded medications use the same active ingredients as brand-name versions, prepared by FDA-registered compounding pharmacies following strict quality standards

Gastrointestinal effects GI side effects dominate the adverse event profile, consistent with all GLP-1 receptor agonists